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Chimeric antigen receptor (CAR) T cell therapy has been used as a targeted approach in 
cancer therapy. Relapsed and refractory acute leukemia in pediatrics has been difficult 
to treat with conventional therapy due to dose-limiting toxicities. With the recent success 
of CD 19 CAR in pediatric patients with B cell acute lymphoblastic leukemia (ALL), this 
mode of therapy has become a very attractive option for these patients with high-risk 
disease. In this review, we will discuss current treatment paradigms of pediatric acute 
leukemia and potential therapeutic targets for additional high-risk populations, including 
T cell ALL, AML, and infant ALL.
Keywords: chimeric antigen receptor, immunotherapy, adoptive, relapsed leukemia, chimeric antigen receptor 
safety, pediatric acute leukemia
introduction
From 1975 to 2010, the overall incidence of pediatric cancer in the US has increased slightly, by an 
average of 0.6% per year (1). Acute lymphoblastic leukemia (ALL) remains the most commonly 
diagnosed malignancy in pediatrics, with approximately 2,900 new cases/year in the United States 
(1). With intensive multi-drug chemotherapy children with standard risk (SR) B-precursor ALL, as 
defined by the NCI/Rome criteria (age 1–9.99 years and initial white blood count <50,000/μL), have 
cure rates of ~90% (2). However due to its high incidence, acute leukemia remains the leading cause 
of death in pediatric patients with cancer. Recent clinical trials have risk-stratified patients based on 
cytogenetics, clinical variables [central nervous system (CNS) and testicular status], and early treat-
ment response (3). Children’s Oncology Group (COG) retrospectively reviewed more than 6,000 
pediatric patients with newly diagnosed ALL and adopted a four-group classification after induction 
therapy: low-risk, average-risk, high-risk, and very high-risk (4). The 4-year event-free survival 
(EFS) varied intensely among the four groups, 91, 86, 76, and 46%, respectively, demonstrating the 
need to identify high-risk patients earlier, and alter therapy accordingly, including the incorporation 
of novel treatment approaches for those patients in the highest risk categories (5). This risk-adapted 
classification aims to give patients the best chance at cure while sparing unnecessary toxicity.
The reality of relapse and/or refractory disease has been a challenge for oncologists as toxicity 
of conventional therapy has limited dose escalation, and EFS for these high-risk patients remains 
suboptimal. Relapse of ALL is defined as disease recurrence at any site after a period of time in which 
the disease was in complete remission. Refractory disease is defined as inability to achieve a complete 
remission despite multiple induction attempts. After relapse, chance of cure significantly diminishes 
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due to acquired mechanism of resistance and poor treatment 
tolerance. With first line chemotherapy intensified to induce a 
remission, leukemic blasts that are present at relapse have been 
exposed to the most effective drug regimens and have gained 
mechanisms that help them survive these cytotoxic agents (6). 
With a combination of chemotherapy and hematopoietic stem cell 
transplant (HSCT), 30–50% of all children with relapsed ALL can 
be cured albeit with the potential for substantial morbidity (7, 8). 
Results from the Children’s Cancer Group (CCG) 1941 marrow 
relapse study showed that 50% of patients failed to enter remis-
sion, died from toxicity, or relapsed again after achieving a brief 
second remission (9). Prognostic factors associated with relapse 
leading to poor outcome include time to relapse, site of relapse, 
cytogenetics, and immunophenotype [T cell ALL, infant ALL, 
acute myeloid leukemia (AML)] (6, 10). This review will focus 
on acute leukemia in pediatrics and discuss current treatment 
paradigms and potential therapeutic targets for immunotherapy.
Acute Leukemia Subtypes in Pediatrics
B Cell Leukemia
Although the majority of patients diagnosed with pre-B cell ALL 
are cured, patients with certain prognostic indicators known thus 
far, such as early relapse, unfavorable cytogenetics, hypodiploidy, 
persistent minimal residual disease (MRD), have more challenges 
achieving and sustaining a remission. Pediatric Oncology Group 
(POG) 9061 aimed at treating patients with isolated CNS relapse 
with intensive chemotherapy and delayed radiation therapy 
(RT). The study showed improved outcomes with a delay in RT 
by 6 months, so more intense systemic chemotherapy could be 
administered. The 4-year EFS for patients with a complete first 
remission (CR1) ≥18 months was 84 ± 5% compared to 46 ± 10% 
for those with CR1 <18  months (p =  0.0002) (11). In support 
of these data, the results of POG 9412 also demonstrated better 
outcome for those patients with isolated CNS relapse with CR1 
≥18 months with a 3-year EFS of 77 ± 7% compared to 52 ± 11% 
EFS for those with CR1 <18 months (p = 0.0267) (12). Historically, 
patients with bone marrow relapse, early and late, have had chal-
lenges entering a CR2 and have had poor overall outcomes. COG 
study AALL01P2 looked at inducing a CR2 in patients with early 
(<36 months from initial CR) or late (>36 months from initial 
CR) medullary relapse with higher intensity induction chemo-
therapy. The 4-month EFS for early and late isolated B-precursor 
marrow relapse were 62 ± 6% (n = 72) and 93 ± 4% (n = 55), 
respectively (13). These results are comparable to previous CCG 
and St. Jude studies. Analysis of relapsed HR-ALL patients treated 
with either standard or augmented post induction therapy on 
CCG 1961 demonstrated that 3-year post-relapse survival 
(PRS) was 30 ± 3.7% (CR1 <36 months) vs. 57.8 ± 6.4% (CR1 
≥36 months), P < 0.0001 (14). Also it showed that patients with 
isolated CNS relapse had better PRS than those with medullary 
relapse, 52.2 ±  7.4 and 29.7 ±  3.7%, respectively (P <  0.001) 
(14). Similarly, St. Jude evaluated 106 patients with isolated or 
combined marrow relapse disease and saw a second remission 
in 66% of early relapse patients vs. 81% of late relapse patients. 
The 5-year EFS estimates for patients with early relapse (CR1 
<36 months) were 12.5 ± 3.9 vs. 42.6 ± 7.8% for patients with 
late relapse (CR1 ≥36  months) (15). Collectively, these results 
demonstrate that early and isolated medullary relapse are poor 
prognostic indicators for patients.
Historically, patients diagnosed with Philadelphia chromo-
some-positive (Ph+) ALL (BCR–ABL fusion) have had poor out-
comes. However, with the discovery of tyrosine kinase inhibitors 
(TKI), this high-risk subgroup has transformed into a leukemia 
that is curable. In childhood Ph+ ALL, imatinib mesylate, one of 
the first TKI, has shown tremendous improvements in 5-year EFS 
when combined with chemotherapy, 70 ± 6 vs. historical controls 
with chemotherapy 35 ± 4% (16). Genetic studies over the last 
decade have identified a Ph-like subtype of leukemia that also has 
dismal outcomes in pediatric patients with ALL. This group does 
not have the typical BCR–ABL fusion protein, but shares a similar 
gene-expression profile to Ph+ ALL (17). It is characterized by 
deletions in genes that are involved in B cell development and 
signaling pathways, IKAROS, PAX5, E2A, among others, and has 
shown resistance to standard chemotherapy (18). In a retrospec-
tive review of 1,700 previously diagnosed patients with pre-B cell 
ALL, 15% of these patients were identified as having Ph-like ALL 
based on genetic studies. Comparative analysis showed that the 
5-year EFS and OS among patients with Ph-like ALL were inferior 
to children with other HR B cell ALL, 58.2 ± 5.3 vs. 83.9 ± 1.5% 
and 72.8 ±  4.8 vs. 92.1 ±  1.1%, P <  0.001, respectively (17). 
This trend was also noted in adolescent and young adult patient 
populations. Further studies in this subpopulation are needed 
to determine if small molecule inhibitors in combination with 
standard chemotherapy can improve remission rates.
Another significant prognostic indicator in children with pre-B 
ALL is blast cell ploidy. Hypoploidy is defined as a karyotype that 
has fewer than 45 chromosomes, and has been associated with 
poor prognosis in pediatric patients with ALL. Approximately 
6% of newly diagnosed B cell ALL patients have hypoploidy, 
which is comprised of high-hypodiploid (45 chromosomes), low-
hypodiploid (36–44 chromosomes), and near-haploid (25–29 
chromosomes) (19). Most patients in this category have blast cells 
with 45 chromosomes, with approximately 1% of patients having 
fewer than 44 chromosomes. In a retrospective review performed 
at St. Jude Children’s Research Hospital, 979 newly diagnosed 
patients with ALL underwent a complete chromosomal analysis 
and 6.8% of patients were identified as having hypoploidy (19). 
Results of this study showed that patients with high-hypodiploid 
had outcomes similar to SR patients; however, patients with blast 
cells <45 chromosomes had significantly inferior 5-year EFS, 
74.9 ± 1.6 vs. 20 ± 10.3%, p < 0.001, respectively (19). In another 
retrospective collaborative review, 130 cases of low-hypodiploid 
(<44 chromosomes) were analyzed and results were similar to 
the St. Jude experience, showing that patients with more than 44 
chromosomes had better EFS and OS than those with <44 chro-
mosomes (5-year EFS 52.2 ± 9.3 vs. 30.1 ± 7.0%, P = 0.01) (20). A 
recent paper by Mehta et al. described 78 pediatric patients with 
hypodiploid ALL who underwent a myeloablative HSCT from 
1990 to 2010 and showed that those children with fewer than 
43 chromosomes had higher mortality and treatment-related 
failures. The 5-year OS for patients with ≤43 chromosomes 
adjusted for disease status and transplant time period was 38 vs. 
71% for those with ≥44 chromosomes, p = 0.01 (21). Thus, more 
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therapeutic studies are needed for this patient population in order 
to achieve higher remission rates.
Minimal residual disease has been shown to be an important 
prognostic marker in patients with ALL. A prospective study by 
Coustan-Smith et  al. looked at MRD in 195 newly diagnosed 
pediatric patients with ALL who received induction therapy. 
MRD positivity was defined as those patients who had ≥0.01% 
of leukemia blasts identified by flow cytometry. This study noted 
a significant difference in the 5-year cumulative incidence of 
relapse of patients who had MRD-positive disease as compared to 
those children who were MRD-negative after induction therapy, 
43 ± 21 vs. 10 ± 3%, P < 0.001 (22). Additionally, a prospective 
study performed by COG assessed 1971 pediatric patients after 
induction therapy. Patients who had MRD ≥0.01% had a 5-year 
EFS of 59 ± 5%, as compared to those who were MRD-negative 
at the end of induction, 88 ± 1%, P < 0.0001 (23). Intensification 
of therapy is currently the standard of care for those patients 
with ALL that have day-29 MRD ≥0.01%. In one recent study, 
Borowitz et  al. showed that intensifying chemotherapy based 
on MRD positivity after induction can improve EFS transiently; 
however, OS and 3-year EFS did not differ (24). Continued trials 
are ongoing to determine if this upstaging improves outcomes for 
this patient population.
In multiple retrospective reviews, MRD appeared to contribute 
significantly to outcomes in pediatric patients after HSCT. In one 
prospective study, 25 patients had MRD testing prior to HSCT, 
with 17 of these patients having MRD-negative disease. Six out 
of eight patients with MRD-positive disease relapsed post HSCT 
as compared to one in the MRD-negative cohort, P < 0.0001 (25, 
26). Additionally, in a recent study performed by COG and the 
Pediatric Blood and Marrow Transplant Consortium (PBMTC), 
144 patients with HR-ALL underwent HSCT and results of this 
study demonstrated that patients who entered transplant with 
MRD ≥0.1% disease had a higher risk of relapse after transplant, 
HR 3.3, P = 0.01 (27). The importance of MRD prior to transplant 
has been emphasized in a recent publication from this study 
where next generation sequencing of the immunoglobulin V(D)
J region was used to identify MRD at very low levels, with no 
relapses occurring in the group that was MRD-negative using this 
ultra-sensitive method (28). Although the use of conventional 
chemotherapeutic agents remains the mainstay of treatment for 
pediatric patients with acute leukemia, those patients with per-
sistent MRD-positivity represent an extremely high-risk group 
that may benefit from novel therapeutic approaches in order to 
eliminate their leukemia burden (26).
Several trials have been performed in order to determine what 
the best treatment course for patients with high-risk acute leuke-
mia should be and results are inconclusive. In a study performed 
by Leung et al., patients with HR-ALL and AML had favorable 
outcomes after HSCT (29). Transplant is thought to be more 
effective than chemotherapy alone due to at least two different 
factors: myeloablative conditioning and graft vs. leukemia (GVL) 
effect. The use of total body irradiation as part of the myeloablative 
conditioning is generally used in patients with ALL to facilitate 
better engraftment and to more effectively eliminate any leukemia 
cells that remain prior to transplant (30, 31), however, whether 
this TBI-based conditioning is more effective than chemotherapy 
only preparative regimens has not been proven in randomized 
trials. Nonetheless, the American Society for Blood and Marrow 
Transplantation (ASBMT) recommends myeloablative TBI 
regimens for all patients with ALL undergoing HSCT based on 
non-randomized data suggesting better survival outcomes (32). 
GVL effect has been confirmed as a contributor to the curative 
potential of allogeneic HSCT for leukemia mediated primarily 
by donor lymphocytes (T cells and natural killer cells) that can 
control MRD and maintain remission. Although the potency of 
GVL for ALL has been challenged, in the above-mentioned COG 
and PBMTC trial, ASCT0431, patients were randomly assigned 
to standard GVHD treatment arm, tacrolimus/methotrexate, 
vs. the experimental arm, sirolimus/tacrolimus/methotrexate. 
The addition of sirolimus did decrease Grades 2–4 acute GVHD 
significantly in patients but did not improve patient survival. It 
was noted that those patients who developed Grade 1–3 acute 
GVHD had an improved EFS, HR 0.5, P = 0.02, suggesting that 
the GVL effect can confer a survival advantage in ALL (27).
In a prospective study of children diagnosed with very high-
risk ALL, as defined by refractory disease, t(9;22) or t(4;11) clonal 
abnormalities, and prednisone-poor response (PPR) associated 
with T immunophenotype and/or WBC count >100  k/mcL, 
patients who underwent a related donor HSCT had an improved 
5-year EFS as compared to those treated with chemotherapy 
alone, 56.7 ± 5.7 vs. 40.6 ± 3.1%, P = 0.02 (33). Berlin–Frankfurt–
Munster (BFM) group and Associazione Italiana Emotologica 
Oncologia Pediatrica (AIEOP) have evaluated patients with 
HR-ALL in first remission and compared their OS with chemo-
therapy alone vs. HSCT. HR criteria in this study included MRD-
positive disease at day 78, induction failure, t(4,11) translocation, 
and PPR. There was no statistically significant difference in EFS 
for patients given HSCT or chemotherapy alone when adjusted 
for time waiting to HSCT (34). Thus, studies on the role for HSCT 
in ALL have been conflicting but most agree that this procedure 
can offer an advantage for at least some high-risk patients (35, 36).
Despite the collaborative efforts of groups worldwide, infants 
with ALL have notably inferior outcomes then older children. 
Traditionally, infants (<365 days old) were treated on HR pro-
tocols with no specificity in regimen; however, this resulted in 
suboptimal outcomes, 3-year EFS ~30% (37). Cooperative trial 
groups, CCG and POG, demonstrated that intensified systemic 
chemotherapy with the addition of intrathecal chemotherapy 
led to improved overall survival as compared to previous stud-
ies (50 vs. 43%) (38). However, overall relapse rate remained a 
major concern, with most relapses occurring within 1 year (39). 
Analysis from multiple cooperative study groups identified sev-
eral prognostic factors that were associated with poor outcomes: 
age <6  months, WBC count >50  k/mcl, MLL rearrangement, 
and CD10 negativity (38–44). Japanese studies were among the 
first to report differences in outcome for patients with germline 
MLL as compared to those with MLL-rearranged disease. One 
hundred and two infants were enrolled on two Japanese studies, 
MLL96/98, with results showing dramatic differences; 22 patients 
with germline MLL had 5-year EFS and OS of 96% vs. 80 infants 
with MLL rearrangement having a 5-year EFS and OS of 39 and 
51%, respectively (42–44). The Interfant Study Group, which 
comprises the largest worldwide collaboration devoted to infant 
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ALL research, also found that infants with germline MLL had 
the best outcome, with a 5-year EFS 74% (40). Additionally, for 
patients treated on Interfant-99, prednisone-good responders 
had more superior 4-year EFS than those with prednisone-poor 
response, 56.4 vs. 29.8%, respectively. Nevertheless, the majority 
of patients with infant ALL continue to have poor outcomes. 
HSCT remains controversial in this subgroup, with some studies 
showing no clinical benefit, and in fact some showing worsened 
outcome in infants with ALL after transplant (45). Interfant-99 
showed no significant difference in EFS comparing patients who 
received chemotherapy vs. HSCT (40).
Flt3 kinase is an important oncogene in adult and pediatric 
AML and has recently become an area for targeted therapeutics 
in infant ALL. Gene-expression studies have shown high levels 
of Flt3 in leukemia blasts in infants and children with MLL-
rearranged leukemia (46). Preclinical data have shown that Flt3 
kinase inhibitors have in  vitro effects, with most pronounced 
response in samples with Flt3 overexpression. The current COG 
protocol incorporates the above prognostic factors and classifies 
patients into three groups based on MLL rearrangement and age. 
In addition to traditional backbone therapy for infant ALL, this 
study, AALL0631, is the first trial to incorporate novel targeted 
therapy, Flt3 inhibitor- CEP-701 (lestaurtinib) (47, 48). Results 
of this study are maturing, however hold promise that small 
molecule inhibitors can improve outcomes for infant ALL.
T Cell Leukemia
Historically, patients diagnosed with T cell ALL had worse prog-
noses than their counterparts with B cell ALL (49). Some reasons 
for this include higher WBC count at presentation, increased 
induction failure, and increased risk of CNS relapse. With the 
implementation of high intensity induction regimens, the EFS 
has increased significantly over the last three decades, from 15–20 
to 50–85% (49). In a retrospective review done by Dana Farber 
Cancer Institute (DCFI), patients with T cell ALL were 8.3 times 
more likely to have an induction failure, and were 2.7 times more 
likely to have CNS relapse than those patients with B cell ALL. 
Despite the significant advances in treatment of T cell ALL, those 
who have relapsed disease have dismal outcomes with 3-year EFS 
reported at <15% (9, 13, 50). In the COG study AALL01P2, only 
2/7 patients with T cell ALL went into a CR2 and no patients with 
T cell ALL survived >1 year from relapse (13). In the BFM-ALL 
87 relapse study, patients with T cell phenotype had an exception-
ally poor outcome, with a 10-year EFS probability estimated at 
15 ± 1.0% (P < 0.001) (50). Thus, novel treatment approaches for 
relapsed T cell ALL are clearly needed.
The existence of a more immature phenotype of T cell ALL has 
been identified in the last decade. Early T cell precursors (ETP) 
are thymocytes that have a distinct immunophenotype (CD1a−, 
CD8−, CD5dim, +myeloid/stem cell marker) and are thought to 
belong to very primitive T cells that have retained multi-lineage 
differentiation potential (51). Patients classified as having ETP-
ALL based on immunophenotyping have done significantly 
worse than more mature T cell phenotype ALL, one review noting 
a 10-year OS for patients with ETP-ALL of 19 vs. 84% for those 
with more mature T cell ALL (51). COG study AALL0434 looked 
prospectively at patients with T cell ALL and categorized them 
into ETP (11%), near-ETP (those with elevated CD5, 17%), and 
not-ETP (72%) based on flow cytometry. In a provocative interim 
analysis, contrary to most prior reports, all three groups showed 
excellent 5-year EFS and OS that were not statistically significant: 
ETP (87, 93%), near-ETP (84, 92%), and not-ETP (87, 92%) using 
the treatment approach employed in this protocol (52). However, 
they did note that patients with ETP and near-ETP had signifi-
cantly higher rates of induction failure, 7.8 and 6.7%, respectively, 
vs. those with not-ETP 1.1% (P < 0.0001) (52). Additionally, this 
study is evaluating whether purine nucleoside analog nelarabine 
will improve outcomes for T cell ALL when combined with front-
line chemotherapy. Nelarabine is a water-soluble prodrug of 
9-B-arabinofuranosylguanine (araG) and inhibits DNA synthesis 
by causing accumulation of araG nucleotides in T cells (53, 54). 
In a phase II pediatric trial with patients receiving single agent 
nelarabine, 106 patients were evaluated and risk-stratified into 
four groups based on first or second relapse with >25% blasts 
in bone marrow (excluding CNS disease), CNS disease, or those 
with <25% relapse in marrow. Response rate was greatest for 
patients with first relapse, 55%, with 16 CR and 2 partial remission 
(PR) (54). These results hold promise for patients with relapsed 
T cell ALL as their overall prognosis is poor with conventional 
therapies, and also could be an option for T cell ALL patients as 
upfront therapy.
Acute Myeloid Leukemia
Acute myeloid leukemia accounts for 20% of newly diagnosed 
acute leukemia in pediatrics and, with the exception of acute 
promyelocytic leukemia, confers a worse prognosis then ALL 
(1). Survival rates for AML have increased dramatically since 
1960 with the introduction of more aggressive induction chemo-
therapy and more intensified regimens. Today, pediatric patients 
diagnosed with AML have ~50–60% overall survival (55). 
Through the efforts of multiple cooperative studies, numerous 
poor prognostic features have been identified; high WBC count, 
monosomy 5 or 7, 5q deletion, FLT3-internal tandem duplication 
(ITD) with high allelic ratio, and patients with MRD at the end 
of the first induction cycle (55–62). In the United Kingdom, the 
Medical Research Council (MRC) AML trial 10 demonstrated 
that response rate after course 1 of induction was highly predic-
tive of outcome, with those achieving CR having an OS of 53%, 
as compared to those with PR, OS 44%, and those with resist-
ant disease, OS 22% (P < 0.0001) (56). Treatment with current 
chemotherapy regimens has reached a plateau, as toxicities will 
likely preclude further increases in intensity. This emphasizes the 
need for more targeted therapies in high-risk pediatric AML.
Flt3 overexpression has been identified as a recurring feature 
of multiple leukemias, and, as seen in infant ALL, has created 
a lot of interest for targeted therapy in AML. Abnormalities in 
the Flt3 gene occur in two ways in AML, point mutations in the 
tyrosine kinase domain and ITDs, which are replicates of three 
nucleotides that maintain an intact reading frame without dis-
rupting the remainder of the gene (58). A proposed mechanism 
of how ITD helps blast cells is by conferring a growth advantage 
and self-renewal capacity (59). In a large retrospective review 
of AML patients in Japan, 43 subjects were identified as hav-
ing Flt3-ITD and had significantly worse 5-year DFS of <20%, 
October 2015 | Volume 3 | Article 805
Shalabi et al. Alternative immunotherapy targets in pediatric leukemia
Frontiers in Pediatrics | www.frontiersin.org
compared to those without Flt3-ITD (5-year DFS of 50%) (57). 
Additionally, multiple CCG studies, 2891, 2941, and 2961, have 
reviewed pediatric patients and identified that Flt3 ITDs were an 
independent poor prognostic factor and that children with an 
ITD allelic ratio >0.4 had poor outcomes as compared to those 
with Flt3-wild type (60, 61). In the most recent COG study, Flt3 
has been added for risk stratification and those with high allelic 
ratio of Flt3–ITD will receive more intensive chemotherapy with 
a Flt3 inhibitor, and will receive a HSCT in first remission (62). 
As discussed above, Flt3 inhibitors are currently being studied 
in pediatric phase III trials, in infant ALL (lestaurtinib) and de 
novo AML with Flt3–ITD (sorafenib). Continued improvement 
in outcomes in high-risk AML will require continued research for 
novel therapeutic agents.
Adoptive Cellular Therapy for Pediatric 
Acute Lymphoblastic Leukemia
Immunotherapy has emerged as a promising treatment for 
patients with relapsed-refractory acute leukemia over the past 
decade. In the simplest sense, the immune system is responsi-
ble for surveying the body and eliminating foreign substances 
that can cause harm, including the clearance of cells that have 
acquired malignant potential. Conceptually, Schreiber et al. has 
described cancer immunosurveillance and cancer progression as 
a cell editing process proceeding through three sequential phases; 
elimination, equilibrium, and escape. If the innate and adaptive 
immune systems are unable to rid the body of highly immuno-
genic transformed cells (elimination phase), the tumor variant 
cells become dormant and undergo additional genetic changes 
in the face of immune pressure (equilibrium phase) (63). If 
immunosurveillance fails to recognize and destroy edited tumor 
cells, tumor evasion mechanisms can be acquired such as loss of 
tumor-associated antigens (TAAs) or down-regulation of major 
histocompatibility complex (MHC) antigens (63, 64). This creates 
a state of immune tolerance which in turn creates a microenvi-
ronment that allows the tumor to flourish (escape phase) (63). 
Genetically engineered T cells using a recombinant T cell recep-
tor (TCR) have been implemented in an attempt to re-direct the 
immune system. This recombinant T cell gains high specificity for 
antigens expressed on tumor cells (65). These engineered TCRs 
showed promise in early clinical trials (64), however had multiple 
limitations; namely, human leukocyte antigen (HLA) restriction 
that limits patient eligibility, dependency on MHC expression by 
tumor cells, and toxicity (65).
More recently, adoptive cellular therapy has now included T 
cells genetically modified using CARs that are independent of 
MHC restriction. The original concept of CARs was first intro-
duced by Gross et al. in 1989, and significant work has been done 
since then to create more sophisticated domains that can enhance 
activation, expansion, and survival of modified T cells (66, 67). 
CARs are customized receptors that are composed of an extracel-
lular antigen-binding domain targeting antigens expressed on the 
malignant cells (such as CD19 expressed on B cell malignancies) 
combined with the intracellular signaling domains of the T cell 
(64). The antigen-binding domain typically consists of single pro-
tein chains derived from monoclonal antibody fragment variable 
regions from heavy and light chains connected by a short linker 
sequence to make a singe chain (scFvs) (67, 68). First-generation 
CARs incorporated only the CD3-ζ chain of the TCR/CD complex 
as the signaling domain but failed to generate potent antitumor 
effects. To improve potency, T cell costimulatory domains have 
now been included generating second (and third) generation 
CARs that incorporate TCR-ζ plus a costimulatory signal such as 
the CD28 endodomain. Indeed, a clinical trial in which patients 
with refractory non-Hodgkin’s lymphoma (NHL) were simulta-
neously infused equal amounts of first generation CD-19 targeted 
CAR T cells, or second-generation CD-19 CAR T cells clearly 
demonstrated that costimulation improved the in vivo expansion 
and persistence of CAR-modified T cells when combined with the 
costimulatory CD28 domain (69). A costimulatory endodomain 
has since been incorporated into most of CAR constructs to 
enhance the signaling strength, persistence, and overall potency 
of the CAR T cells (70). Multiple costimulatory domains are 
currently being investigated, CD28, 4-1BB, OX40, ICOS, and 
DAP10; however, no consensus has been reached regarding 
which costimulatory domain is superior.
Antigen Selection in B ALL
Genetically engineered T cells have become a more realistic option 
for those patients with refractory or multiply relapsed acute leu-
kemia for which conventional therapies have failed. Hematologic 
malignancies have been a prime example in the development of 
antibody-based immunotherapy (including CAR T cells which 
use an antibody-derived binding domain) because of cell surface 
antigens well known through flow cytometry; many of which 
have restricted expression to hematopoietic lineages with poten-
tial for regeneration of the non-malignant cells expressing the 
same target after completion of therapy. Ideally, an antigen target 
is one that has high expression on the malignant cell surface, and 
is not detected on normal tissues (or at least limited), therefore 
maximizing selectivity and minimizing off-tumor toxicity (71). 
In the context of cell therapy for leukemia, CD19 has been the 
most targeted antigen thus far with multiple trials centered on 
relapsed or refractory acute B cell leukemia using anti-CD19 
antibodies. This antigen is solely expressed on B cell lineage, 
sparing other normal tissues, and is highly expressed on B ALL. 
Blinatumamab is a bispecific T cell engaging antibody (BiTE), 
anti-CD19/CD3, that has shown efficacy in adult and pediatric 
patients with relapsed or refractory ALL (72, 73). In a phase I/
II pediatric study, 32% of pediatric patients with refractory ALL 
entered into a cytologic complete remission. Currently, a multi-
center phase II/III trial (AALL1331) is underway to determine 
if using blinatumamab in upfront relapsed leukemia therapy 
increases leukemia-free survival in pediatric patients.
CD19 CAR therapy has revolutionized immunotherapy 
for hematologic malignancies with major success in multiple 
pediatric phase I studies (74, 75). In one of the largest pediat-
ric studies to date, 30 patients were included, with 25 patients 
<22 years old. The CAR construct used was a second generation 
with a 41-BB costimulatory domain. Morphologic complete 
remission was induced in 27/30 patients, with 81% of those hav-
ing MRD-negative disease. The 6-month EFS was 67% and OS 
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was 78% (74). Lee et al. conducted a phase 1 study with CD19 
second-generation CAR using a CD28 costimulatory domain in 
21 patients and had a CR of 67%, with 12 patients (86%) achieving 
MRD-negative disease. OS was 56% for patients with a median 
of 10  months followup. Of those with MRD-negative disease, 
10 of them went on to HSCT and all remained disease free at 
10 months post HSCT (75). A novel mechanism of tumor escape 
has emerged with CAR and bispecific antibody therapy resulting 
in relapses with leukemia that no longer express the targeted 
CD19 epitope (74–76). The loss of antigen is a potential hurdle in 
the development of immunotherapy, thereby making it impera-
tive to develop strategies to optimize, including the identification 
of additional targets.
CD22 is another common B-lineage marker that is expressed 
on leukemia and for which immunotherapeutic targeting has 
recently been developed. Two different CD22 immunotoxins 
have been tested against B ALL in clinical trials. In a phase 1 
study, moxetumomab pasudotox (anti-CD22 pseudomonas 
exotoxin conjugate) showed activity in pediatric patients who 
had refractory disease. Twenty-three patients were enrolled in 
this phase 1 study and 7/23 patients either had a PR (with >50% 
blast reduction) or a CR (77, 78). Another CD22 immunotoxin 
(inotuzomab) has been tested primarily in adults with ALL and 
has demonstrated overall response rates of 58% in relapsed and 
refractory adult patients with acute lymphocytic leukemia (79). 
Recently, a CD22 CAR has been developed and shown to have 
comparable activity in murine xenografts when compared to 
CD19 CAR (80). A phase I study is underway using a CD22 CAR 
in patients with relapsed/refractory acute leukemia.
In order to identify novel antigenic targets and to improve 
selectivity for malignancy, flow cytometric and genomic data have 
been analyzed. A bioinformatics approach using gene-expression 
databases (containing multiple tumor samples annotated often 
with additional clinical and laboratory information) compares 
expression profiles between normal tissues and tumors of inter-
est and can identify potential targets with a favorable expression 
profile. For example, genomic profiling of ALL has demonstrated 
recurring abnormalities in the CRLF2 gene resulting in overex-
pression of the encoded protein TSLPR in approximately 5–10% 
of B ALL. Importantly, overexpression of CRLF2 seems to confer 
a risk of relapse. As a cell surface protein, this oncogenic protein 
can be targeted immunotherapeutically. In fact, a TSLPR CAR 
has demonstrated potent activity in preclinical models (81). 
The large set of genomic data generated by expression profiling 
and next generation sequencing can be further analyzed using 
algorithms that “filter” for predicted cell surface expression. This 
approach has been applied to a number of pediatric malignancies, 
including B cell ALL and T cell ALL (82, 83).
To combat common toxicity seen in CD 19 trials, a more 
specific targeted CAR has been created in order to try and mini-
mize B cell aplasia. Exploiting the monoclonality of malignant 
B cells, a recent phase I study used clonal restriction to create a 
k-light chain CAR that specifically targets k+ leukemia and lym-
phomas. Ten patients have been treated to date, with three dose 
levels assessed. Results of five NHL patients have showed promise 
with two patients entering a CR and one other showing partial 
response. This preliminary study has shown that CAR therapy 
restricted to k-light chain has been effective in patients with k+ 
lymphoma with diminished effects on the non-malignant B cell 
population (84).
immunotherapeutic Targets in Pediatric 
T Cell ALL
As reported in Orentas et  al. 2014, Gene Expression Omnibus 
(GEO) data containing over 100 samples of T cell ALL were 
analyzed to determine which genes encoding cell surface proteins 
were most overexpressed in pediatric T cell leukemia in order to 
identify novel antigens that may be amenable to targeted therapy. 
One of the top transcripts that was notably overexpressed in T cell 
ALL as compared to PBMCs was TALLA (83). TALLA has been 
previously described by Seon et al. in the 1980s as a hybridoma 
monoclonal antibody that had specific target selectivity for T 
cell leukemia. Hara and Seon showed that this hybridoma, when 
injected in mice with T cell leukemia, resulted in in vivo suppres-
sion of tumor growth without overt toxicity (85, 86). Using gene-
expression data combined with known activity of a monoclonal 
antibody, TALLA may be an area of future research in relapsed or 
refractory T cell ALL but will require validation that this antigen 
is expressed on the surface of the majority of primary T cell ALL 
samples.
As discussed previously, ETP-ALL has typically been more 
difficult to treat, with more induction failure than patients with 
more mature T cell ALL. Recently, in preclinical studies, Maude 
et  al. demonstrated aberrant JAK/STAT pathway in ETP-ALL 
patient samples. Patient-derived xenograft models were estab-
lished and ruxolitinib, a JAK1/2 inhibitor, demonstrated robust 
activity as a single agent, with a statistically significant reduction 
in peripheral blasts as compared to controls in 5/6 xenograft 
models. Continued work is needed in this area to further establish 
targets for novel treatments (87).
Mamonkin et al. recently developed a CAR directed at CD5 
for T cell ALL that showed promising in vitro and in vivo activity. 
They demonstrated that CD5 CAR T cells were cytotoxic to five 
different CD5+ T cell ALL and T cell lymphoma lines in vitro, 
and had no effect on CD5− lines (88). Additionally, they were 
able to show that these CD5 CAR T cells had tumor suppression 
capabilities when co-cultured for longer periods of time with 
these CD5+ cell lines. They were also able to show in vivo activity 
of CD5 CAR T cells against T cell ALL in xenograft models, both 
when infused early and late after leukemia injection was given. 
Xenografts treated with experimental CD5 CAR T cells had 
statistically significant survival advantage as compared to control 
groups given CD 19 CAR (88). However, complete eradication 
was not seen in these models and leukemia blasts retained CD5 
cell surface expression, suggesting lack of persistence of CAR. 
One of the major challenges of producing a CAR T cell directed 
at an antigen on most naïve T cells is protecting healthy T cells 
from destruction by CAR therapy. These authors concluded that 
self-killing of T cells was limited; T cells co-cultured with CD5 
CAR initially declined in number, however had comparable 
sustained expansion when compared to the control CD19 CAR 
used (88). These data are promising in light of new antigens being 
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discovered specifically for a disease subtype in pediatrics that has 
limited options in targeted therapy.
CARS in Pediatric AML
As stated above, pediatric patients with relapsed AML have lim-
ited therapeutic options with HSCT providing the only curative 
potential. Inducing a remission in order to get to transplant in 
these relapsed patients becomes challenging due to chemorefrac-
tory disease. CD33 targeting has been an area of investigation in 
pediatric AML, as seen with the anti-CD33 monoclonal antibody, 
Gemtuzumab ozogamicin (GO). In a pediatric clinical trial, it 
appeared that children receiving GO had a statistically signifi-
cantly improved 3-year EFS, 53 vs. 47% (P = 0.05), however the 
overall survival did not differ in the groups, thus it was unclear 
if GO had any added benefit (89). Several studies are ongoing 
testing the efficacy of CD33-directed CAR therapy. Kenderian 
et  al. developed four constructs using the scFv region of GO 
and tested these targeted agents against AML cell lines, patient 
AML samples, and xenografts. The CD33 CARs demonstrated 
significant cytotoxicity and cellular degranulation against AML 
cell lines, with significant in vitro activity against primary AML 
samples as well. Significant reduction in tumor burden and a 
survival advantage was seen in mice injected with CD33 CAR 
vs. those injected with control T cells (90). Toxicity associated 
with this CAR resulted in decrease in myeloid progenitor cells, 
which was expected based on CD33 expression (90). Similarly, 
O’Hear et al. recently described a novel second-generation CD33 
CAR that incorporated 41-BB costimulatory endodomain used 
in preclinical models. AML cell lines, xenografts, and primary 
pediatric samples were assessed. Specific tumor killing of CD33+ 
AML cell lines was seen when co-cultured with CD33 CAR, and 
these cultures had higher levels of cytokines when compared to 
the cell lines co-cultured with control vector transduced T cells. 
This same result was seen with primary AML samples, and inter-
estingly, the extent of killing did not correlate with the cell surface 
level of expression of CD33 (91). Additionally, xenografts were 
established and studied in two ways: (1) to determine if CAR T 
cells could prevent the development of AML and (2) to determine 
if CAR T cells could treat AML. Mice were injected with AML 
and, in the first model, were immediately injected with either 
CAR T cells, viral transduced T cells, or saline. Results showed 
rapid development of leukemia in the two control groups with 
<1% of AML cells detected in those injected with CAR T cells. 
Also in established leukemia models, treated as per the three 
groups above, CAR T cells resulted in significant reduction in 
tumor burden with a statistically significant survival advantage 
compared to mice treated with control cells (91). Results of these 
preclinical models are promising for creating a CAR construct to 
combat relapsed or refractory AML.
In an attempt to overcome the significant hematopoietic 
toxicity associated with CD33 targeted therapy, Kenderian et al. 
developed a transient CAR using electroporation of T cells with 
RNA-modified CD33 CAR. Results of this preclinical model 
showed similar eradication of leukemia cells as compared to 
lentiviral transduced CD33 CAR, albeit transient in vitro activity. 
It was then combined with chemotherapy in vivo and shown to 
have cytotoxic effects with enhanced CAR persistence (90). This 
safety mechanism provided by transient persistence is important 
as it could avoid prolonged myelosuppression in AML patients.
Multiple groups have recently reported preclinical activity 
against CD123 in AML. Pizzitola et al. recently described activity 
with cytokine-induced killer cells (CIK) that had been geneti-
cally modified to express CD33-CAR and CD123-CAR. What 
they found was that mice treated with CIK with either CD33 or 
CD123 bound CAR had significant reduction in tumor burden 
than those in the control group. Interestingly, when leukemia 
returned, analysis was performed and residual AML cells con-
tinued to express CD33/123, thus concluding that these cells did 
not develop the resistance mechanisms employed as previously 
described in CD19 CAR immunotherapy (92). Also, Tettamanti 
et al. recently described CD123 as a potent AML target due to 
its high expression on AML cells and AML leukemia stem cells 
(AML-LSCs) and low levels of expression on hematopoietic 
stem cells. In vitro studies demonstrated CIK with anti-CD33 or 
anti-CD123 had equal AML cytotoxic effects; however, CD123-
CAR had a safer toxicity profile toward progenitor cells (93). 
Similarly, Mardiros et al. developed a CD123-CAR that showed 
specific activity against primary AML samples, in addition to 
in  vivo activity in xenograft AML models. This study showed 
delayed leukemia relapse in xenografts treated with CAR therapy 
vs. mock T cells; however, the treatment group did not have 
any long-term survivors (94) Gill et  al. recently demonstrated 
CD123-CAR activity in primary samples and xenograft models, 
and was able to show long-term survivors after treatment with 
CD123-CARs. This study differed from the others in that they saw 
significant hematopoietic progenitor toxicity with their CD123-
CAR, recommending usage as a bridge or conditioning regimen 
for HSCT (95). Finally, CAR T cells targeting the Lewis Y antigen 
and the folate receptor β have also shown activity against AML 
(96, 97). Thus, there are multiple potential targets for CAR T cells 
in AML. However, it remains to be seen whether clinical activity 
will be as good as that seen with CD19 CAR T cells in ALL and 
the extent to which toxicity against non-malignant myeloid cells 
limit development.
The Potential of Combinatorial CAR 
Targeting in Pediatric Leukemia
Due to its universal expression on B cell malignancies, CD19 
has been an attractive target for CAR-directed therapies. Its 
success hinges on the fact that although CD19 is expressed on 
normal B cells, the toxicity associated with aplasia of this cel-
lular compartment is tolerable as seen in recent trials (74, 75). 
Targeting of other acute hematologic malignancies, AML and 
T cell ALL, has been more challenging. Targeting cell surface 
molecules universal to these cell types is often detrimental to 
normal myeloid and T cell compartments, making it extremely 
difficult to identify highly specific CAR targets. In order to 
potentiate antitumor activity, and reduce off-tumor toxicity of 
normal cellular compartments, combinatorial approaches are 
being developed (Figure  1). This proof of concept was intro-
duced by Grada et al. as a tandem CAR using CD19 and HER2 
as antigens. This construct was shown to have activity against cell 
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lines that had single antigens in addition to having synergistic 
effect when both antigens were simultaneously encountered 
(98). Kloss et  al. used a combinatorial approach transducing 
T cells with both a CAR that provides suboptimal activation 
upon binding of one antigen, and a chimeric costimulatory 
receptor that binds a second antigen. Using T cells that were 
co-transduced with two prostate antigens, tumors expressing 
both antigens were effectively targeted and destroyed while 
sparing tumors that expressed one sole antigen (99). Lanitis et al. 
identified two potential antigen targets for CAR development for 
use in epithelial ovarian cancers using mesothelin (meso) and 
a-folate receptor (Fra). Ovarian tumors generally overexpress 
both these antigens, while coexpression on normal tissues is 
rare. Two separate CARs were created, one with T cell activation 
signal 1 (meso-CD3ζ) and the other with costimulatory signal 
2 (Fra-CD28), and T cells where then transduced to co-express 
both CARs. By using this physical separation barrier, only cells 
expressing both antigens would bind and elicit complete T cell 
activation needed for antitumor activity. This preclinical model 
demonstrated potent anticancer activity in  vitro and in  vivo 
that was superior to first-generation CARs and comparable to 
standard second-generation CARs. The major advantage of this 
new combinatorial CAR over a standard second-generation 
CAR was dissociated signaling of two antigens yielded a better 
side effect profile against cross-reactivity with normal healthy 
tissues expressing a single antigen (100).
FiGURe 1 | (A) Second-generation CAR engages the selected target antigen and produces complete T-cell activation through signal 1 provided by the TCR–zeta 
and signal 2 provided by costimulatory endodomain 41-BB. (B) Combinatorial CAR T-cell that has two antigens; CAR A provides signal 1 when engaged with Target 
A and CAR B provides signal 2 when engaged with Target B. Neither signal can trigger complete T-cell activation individually, sparing healthy tissue that express one 
of the antigens.
Combinatorial targeting approaches may be particularly 
well suited for pediatric acute leukemia, specifically AML 
and T cell ALL that express multiple hematopoietic antigens. 
Additionally, varying reports (10–30%) of aberrant lymphoid or 
myeloid-associated markers have been demonstrated in pediat-
ric studies of patients with acute leukemia. Conflicting reports 
as to the prognostic implications of aberrant phenotypes have 
been shown in prospective pediatric studies performed in the 
1990s (101–103). Pui et al. found that 16% of pediatric patients 
consecutively enrolled on clinical trials had aberrant expression 
of myeloid antigens on their ALL blasts, however found that it 
did not have an effect on remission or EFS (101). On the other 
hand, Wiersma et al. found that 22% of newly diagnosed pediatric 
patients expressed myeloid antigens on their leukemia blasts and 
in a multivariate analysis, it was found to be the most significant 
poor prognostic predictor of relapse in childhood ALL (102). 
Although the prognostic significance remains controversial, the 
presence of aberrant myeloid antigens is a common occurrence in 
childhood ALL (104, 105). Using this to our advantage, one could 
construct a combinatorial CAR that has more specificity for these 
leukemia blasts and spare normal HSCs.
Other Approaches to improve Safety
Careful selection of TAAs is of paramount importance due to the 
potency of genetically modified T cells and the potential on-target, 
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off-tumor toxicity that has been reported. One patient treated for 
metastatic colon cancer with Her2/neu CAR T cells died 5 days later 
from respiratory failure attributable to cytokine storm potentially 
due to low levels of Her2/neu found in lung epithelium (106). 
This highlights the importance of assessing for cross-reactivity 
on normal cells during the preclinical development of genetically 
engineered cells. However, it is likely that it will be challenging 
to identify antigens that are exclusively expressed on tumor cells 
or that are expressed only by normal cells for which off-tumor 
toxicity will be tolerated (such as CD19 on B cells). Indeed, 
patients responding to CD19-CAR therapy develop B cell aplasia 
noted that can be managed by immunoglobulin infusions. Thus, 
approaches to control expansion or persistence of genetically 
engineered cells will be important for the clinical development. 
For example, inducible caspase 9, an intrinsic apoptotic pathway, 
can be incorporated into CAR T cell as a “suicide gene.” Following 
an allogeneic transplant, patients were given a donor lymphocyte 
infusion of cells modified to express the inducible caspase 9 
gene, and had more than 90% of T cells eliminated in 30  min 
when given 1 dose of a dimerizing drug (107). This construct is 
currently being incorporated into CAR T cells in the context of 
clinical trials. Additionally, the use of RNA electroporated CAR 
constructs allows for transient expression of CAR in T cells with 
retention of potent activity provides a possible strategy to improve 
the safety of CAR T cell therapy (90, 108) Finally, using CAR T 
cells that express a truncated EGFR can be used as a safety feature 
for hematologic CAR targeted therapy. Human epidermal growth 
factor receptor is not expressed on cells of the hematopoietic and 
lymphopoietic systems; therefore, it will not have an impact on 
progenitor cells. Using truncated EGFR-CAR is helpful as it pro-
vides a cell surface marker for in vivo tracking of adoptive T cell 
therapy. When therapy is completed or toxicities have been noted, 
administration of a monoclonal antibody, cetuximab, results in 
in vivo cell ablation, thereby employing a safety mechanism that 
can ameliorate potential long-term CAR side effects (109).
A relatively common and potentially life-threatening toxicity 
seen in CD19 CAR trials is cytokine-release syndrome (CRS), a 
systemic, immune-mediated inflammatory response. CRS ranges 
in severity from mild (fevers and myalgia) to life threatening 
(capillary leak, respiratory failure, hypotension) and is often cor-
related with high peak levels of IL-6, C-reactive protein, ferritin, 
and IL-2 (P < 0.05) (74, 75). It was also noted that higher patient 
blast percentages prior to therapy correlated with more severe 
CRS and that CRS is often associated with clinical response (74). 
For those with more severe CRS, IL-6 blockade and/or gluco-
corticoids can mediate rapid improvement (74, 75). Thus, there 
is interest in developing standard approaches for intervention. 
As suggested by Lee et  al., creating an algorithm where IL-6 
blockade is used as the first line therapy for treatment of severe 
CRS can systematically guide therapy for CRS perhaps avoiding 
mortality (75).
Conclusion
Exceptional progress has been made over the last two decades 
with genetically modified T cells with recent dramatic success 
using CAR T cells for pediatric leukemia. With continued 
identification of targets, the possibilities of CAR therapy 
continue to expand. Careful preclinical and clinical develop-
ment will be required for the safe and successful incorporation 
of genetically modified T cells into treatment paradigms for 
cancer. Almost certainly, approaches to manage potential 
toxicity to non-malignant tissues due to on-target, off-tumor 
reactivity will be required. One strategy is the development 
of combinatorial therapy using T cells expressing multiple 
CAR constructs thus controlling reactivity based on expres-
sion of combinations of targets. Pediatric leukemia may be 
particularly amenable to such approaches due to aberrant 
expression of cell surface molecules not typically found on 
normal hematopoietic cells.
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